Departments of Pathology and Molecular Medicine (Kavsak, Hill, McQueen), Health Research Methods, Evidence and Impact (Ma, Griffith); and Medicine (Clayton); Division of Emergency Medicine (Shortt, Sherbino, Worster); Division of Cardiology (Mehta, Devereaux); Population Health Research Institute (Devereaux), McMaster University, Hamilton, Ont.; Department of General and Interventional Cardiology (Neumann, Ojeda, Westermann, Sörensen, Blankenberg), University Heart Center Hamburg Eppendorf, Hamburg, Germany; Royal Brisbane and Women's Hospital (Cullen, Greenslade, Parsonage), Brisbane, Australia; Christchurch Hospital (Than, Pickering, Troughton, Aldous), Christchurch, New Zealand; Department of Medicine and Christchurch Heart Institute, University of Otago (Richards, Pickering, Troughton, Pemberton), Christchurch, New Zealand; Cardiovascular Research Institute (Richards), National University of Singapore
Departments of Pathology and Molecular Medicine (Kavsak, Hill, McQueen), Health Research Methods, Evidence and Impact (Ma, Griffith); and Medicine (Clayton); Division of Emergency Medicine (Shortt, Sherbino, Worster); Division of Cardiology (Mehta, Devereaux); Population Health Research Institute (Devereaux), McMaster University, Hamilton, Ont.; Department of General and Interventional Cardiology (Neumann, Ojeda, Westermann, Sörensen, Blankenberg), University Heart Center Hamburg Eppendorf, Hamburg, Germany; Royal Brisbane and Women's Hospital (Cullen, Greenslade, Parsonage), Brisbane, Australia; Christchurch Hospital (Than, Pickering, Troughton, Aldous), Christchurch, New Zealand; Department of Medicine and Christchurch Heart Institute, University of Otago (Richards, Pickering, Troughton, Pemberton), Christchurch, New Zealand; Cardiovascular Research Institute (Richards), National University of Singapore.
CMAJ. 2018 Aug 20;190(33):E974-E984. doi: 10.1503/cmaj.180144.
Testing for high-sensitivity cardiac troponin (hs-cTn) may assist triage and clinical decision-making in patients presenting to the emergency department with symptoms of acute coronary syndrome; however, this could result in the misclassification of risk because of analytical variation or laboratory error. We sought to evaluate a new laboratory-based risk-stratification tool that incorporates tests for hs-cTn, glucose level and estimated glomerular filtration rate to identify patients at risk of myocardial infarction or death when presenting to the emergency department.
We constructed the clinical chemistry score (CCS) (range 0-5 points) and validated it as a predictor of 30-day myocardial infarction (MI) or death using data from 4 cohort studies involving patients who presented to the emergency department with symptoms suggestive of acute coronary syndrome. We calculated diagnostic parameters for the CCS score separately using high-sensitivity cardiac troponin I (hs-cTnI) and high-sensitivity cardiac troponin T (hs-cTnT).
For the combined cohorts ( = 4245), 17.1% of participants had an MI or died within 30 days. A CCS score of 0 points best identified low-risk participants: the hs-cTnI CCS had a sensitivity of 100% (95% confidence interval [CI] 99.5%-100%), with 8.9% (95% CI 8.1%-9.8%) of the population classified as being at low risk of MI or death within 30 days; the hs-cTnT CCS had a sensitivity of 99.9% (95% CI 99.2%-100%), with 10.5% (95% CI 9.6%-11.4%) of the population classified as being at low risk. The CCS had better sensitivity than hs-cTn alone (hs-cTnI < 5 ng/L: 96.6%, 95% CI 95.0%-97.8%; hs-cTnT < 6 ng/L: 98.2%, 95% CI 97.0%-99.0%). A CCS score of 5 points best identified patients at high risk (hs-cTnI CCS: specificity 96.6%, 95% CI 96.0%-97.2%; 11.2% [95% CI 10.3%-12.2%] of the population classified as being at high risk; hs-cTnT CCS: specificity 94.0%, 95% CI 93.1%-94.7%; 13.1% [95% CI 12.1%-14.1%] of the population classified as being at high risk) compared with using the overall 99th percentiles for the hs-cTn assays (specificity of hs-cTnI 93.2%, 95% CI 92.3-94.0; specificity of hs-cTnT 73.8%, 95% CI 72.3-75.2).
The CCS score at the chosen cut-offs was more sensitive and specific than hs-cTn alone for risk stratification of patients presenting to the emergency department with suspected acute coronary syndrome. : ClinicalTrials.gov, nos. NCT01994577; NCT02355457.
检测高敏心肌肌钙蛋白(hs-cTn)可能有助于分诊和临床决策,适用于因急性冠状动脉综合征出现症状而就诊于急诊科的患者;然而,这可能会因分析变异或实验室误差而导致风险分类错误。我们旨在评估一种新的基于实验室的风险分层工具,该工具将 hs-cTn、血糖水平和估算肾小球滤过率的检测结果纳入其中,用于识别因急性冠状动脉综合征而就诊于急诊科的患者中存在心肌梗死或死亡风险的患者。
我们构建了临床化学评分(CCS)(范围 0-5 分),并使用涉及因疑似急性冠状动脉综合征而就诊于急诊科的患者的 4 项队列研究的数据,将其作为 30 天内心肌梗死(MI)或死亡的预测指标进行验证。我们分别使用高敏心肌肌钙蛋白 I(hs-cTnI)和高敏心肌肌钙蛋白 T(hs-cTnT)计算 CCS 评分的诊断参数。
对于合并队列(n=4245),17.1%的患者在 30 天内发生 MI 或死亡。CCS 得分为 0 分可最佳识别低危患者:hs-cTnI CCS 的敏感性为 100%(95%置信区间 [CI] 99.5%-100%),其中 8.9%(95% CI 8.1%-9.8%)的人群被归类为 30 天内发生 MI 或死亡的低危人群;hs-cTnT CCS 的敏感性为 99.9%(95% CI 99.2%-100%),其中 10.5%(95% CI 9.6%-11.4%)的人群被归类为低危人群。CCS 的敏感性优于单独的 hs-cTn(hs-cTnI <5ng/L:96.6%,95% CI 95.0%-97.8%;hs-cTnT <6ng/L:98.2%,95% CI 97.0%-99.0%)。CCS 得分为 5 分可最佳识别高危患者(hs-cTnI CCS:特异性 96.6%,95% CI 96.0%-97.2%;11.2%[95% CI 10.3%-12.2%]的人群被归类为高危人群;hs-cTnT CCS:特异性 94.0%,95% CI 93.1%-94.7%;13.1%[95% CI 12.1%-14.1%]的人群被归类为高危人群),与使用 hs-cTn 检测的总体第 99 百分位数相比(hs-cTnI 的特异性为 93.2%,95% CI 92.3-94.0;hs-cTnT 的特异性为 73.8%,95% CI 72.3-75.2)。
与单独使用 hs-cTn 相比,CCS 评分在选定切点时更敏感和特异,可用于分诊因疑似急性冠状动脉综合征而就诊于急诊科的患者。